PACAP 38 inhibits adiponectin release

Neuro Endocrinol Lett. 2007 Apr;28(2):166-9.

Abstract

Background: Pituitary adenylate cyclase activating peptide (PACAP 38) is a neuropeptide with anti-inflammatory activity. Vasoactive intestinal peptide (VIP)/PACAP receptors are found in immune cells, endocrine glands and also in adipose tissue. Adiponectin is an adipocyte-derived protein hormone which possesses anti-inflammatory, antidiabetic and antiatherogenic properties. The aim of this study was to examine the influence of PACAP 38 on adiponectin release in basal conditions and during lipopolysaccharide (LPS)-induced acute inflammation.

Methods: Male Wistar-Kyoto rats were divided into four groups which received intraperitoneal injections of 0.9% NaCl, LPS, PACAP 38 or LPS+PACAP 38, respectively. Serum adiponectin concentrations were measured using an ELISA test.

Results: LPS administration did not change adiponectin concentration; however, PACAP 38 administered alone decreased serum adiponectin concentration after 2 h (p<0.05) and 4 h (p<0.01). In the group that received LPS+PACAP38, compared with LPS alone, no difference in adiponectin concentration was observed.

Conclusions: We conclude that PACAP 38 may directly modulate adiponectin secretion by adipocytes in basal conditions.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adiponectin / blood
  • Adiponectin / metabolism*
  • Animals
  • Inflammation / chemically induced
  • Injections, Intraperitoneal
  • Lipopolysaccharides
  • Male
  • Pituitary Adenylate Cyclase-Activating Polypeptide / administration & dosage
  • Pituitary Adenylate Cyclase-Activating Polypeptide / pharmacology*
  • Rats
  • Rats, Inbred WKY

Substances

  • Adiponectin
  • Lipopolysaccharides
  • Pituitary Adenylate Cyclase-Activating Polypeptide